BET Bromodomain Inhibition Promotes Anti-Tumor Immunity by Suppressing PD-L1 expression

Restoration of anti-tumor immunity by blocking PD-L1 signaling using antibodies has proven to be beneficial in cancer therapy. Here we show that BET bromodomain inhibition suppresses PD-L1 expression and limits tumor progression in ovarian cancer. CD274 (encoding PD-L1) is a direct target of BRD4-me...

Full description

Saved in:
Bibliographic Details
Published in:Cell Rep
Main Authors: Zhu, Hengrui, Bengsch, Fee, Svoronos, Nikolaos, Rutkowski, Melanie R., Bitler, Benjamin G., Allegrezza, Michael J., Yokoyama, Yuhki, Kossenkov, Andrew V., Bradner, James E., Conejo-Garcia, Jose R., Zhang, Rugang
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5177024/
https://ncbi.nlm.nih.gov/pubmed/27626654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.08.032
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items